Clinical trials: Drug Withdrawal
HIV Infections
Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV
Long-term control of HIV depends on improvement in an individual's immune system. The purpose of this study is to see if either stopping anti-HIV drugs for short periods of time and/or adding a vaccine to the anti-HIV drugs being…
- Trial name
- NCT00011011
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452)
- Where
- 16 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Migraine, Hemicrania
Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency
Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine population. Medication overuse (MO) makes this condition very difficult to treat.
- Trial name
- MOHC (NCT04410536)
- Testing
- Symptomatic drugs, Bridge therapy, Mindfulness program
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Neonatal Opioid Withdrawal Syndrome
Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome
The goal of this observational study is to learn how two medicines used in routine care-buprenorphine and morphine-affect recovery in newborns (≥36 weeks' gestation) with Neonatal Opioid Withdrawal Syndrome (NOWS).
- Trial name
- TreaT NOW (NCT07278375)
- Where
- 22 sites in United States
- Volunteers
- 796 people
- Sponsor
- HELP for NOWS Consortium
Alagille Syndrome
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as…
- Trial name
- ICONIC (NCT02160782)
- Testing
- LUM001 (Maralixibat)
- Where
- 9 sites in Australia, Belgium and 4 more
- Volunteers
- 31 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Heroin Dependence, Morphine Dependence
Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for inpatient opiate detoxification.
- Conditions
- Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00032955
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in United States
- Volunteers
- 163 people
- Sponsor
- University of California, Los Angeles
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
Cocaine Dependence
Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse
This is a residential pilot trial to evaluate the pharmacodynamic interaction between zonisamide and cocaine, with the goal of evaluating zonisamide's potential for the treatment of cocaine dependence.
- Trial name
- NCT01137890
- Testing
- Zonisamide, Cocaine Hydrochloride, Neurocognitive and Performance Battery
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Alcohol Use Disorder, Addiction
Portrayal of Hospital Alcohol Detoxification in France
Even if hospital alcohol detoxifications are frequent in France, their caracteristicscharacteristics remain unknown. The investigators aim to describe the clinical and paraclinical caracteristicscharacteristics of their patients…
- Conditions
- Alcohol Use Disorder, Addiction, Alcohol Withdrawal Syndrome
- Trial name
- Alcostop (NCT04973202)
- Testing
- Stay for alcohol detoxification
- Where
- France
- Volunteers
- 50,000 people
- Sponsor
- University Hospital, Montpellier
Cannabis Withdrawal
Effect of PP-01 on Cannabis Withdrawal Syndrome
This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to…
- Trial name
- NCT05494437
- Testing
- PP-01 High Dose, PP-01 Low Dose, Nabilone
- Where
- 18 sites in United States
- Volunteers
- 234 people
- Sponsor
- PleoPharma, Inc.
Neonatal Abstinence Syndrome
Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome
The purpose of this study is to examine the efficacy of a specially-constructed crib mattress that delivers gentle vibrations (stochastic vibrotactile stimulation) as a complementary, non-pharmacological intervention for treating…
- Trial name
- NCT02801331
- Testing
- Stochastic Vibrotactile Stimulation (SVS)
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Elisabeth B Salisbury
Alcoholism
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU
Background: Alcohol is the leading psychoactive substance consumed in France, with about 15 million regular consumers. The National institute on Alcohol Abuse and Alcoholism (NIAAA) considers alcohol abuse to be more than 14…
- Trial name
- BACLOREA (NCT02723383)
- Testing
- BACLOFEN
- Where
- 18 sites in France
- Volunteers
- 314 people
- Sponsor
- Nantes University Hospital
Post-Traumatic Stress Disorders, Stress Disorders
Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings
The purpose of this study is to evaluate Cognitive-behavioral therapy (CBT) for deployment-related post-traumatic stress disorder (PTSD) that can be used by behavioral health consultants working with Service Members in the…
- Conditions
- Post-Traumatic Stress Disorders, Stress Disorders, Combat Disorders
- Trial name
- NCT00974402
- Testing
- Cognitive Behavioral Therapy
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cystic Fibrosis, Drug Withdrawal
Qualitative Understanding of Experiences With the SIMPLIFY Trial
This qualitative longitudinal study is designed to elicit and thematically analyze the perspectives of SIMPLIFY subjects about treatment withdrawal research and treatment burden in the context of triple combination CFTR (Cystic…
- Trial name
- QUEST (NCT04320381)
- Testing
- Qualitative Interview
- Where
- 2 sites in United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Opioid-Related Disorders, Substance Withdrawal Syndrome
Effects of Dynorphin 1-13 on Heroin Addiction - 1
The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses…
- Trial name
- NCT00000244
- Testing
- Dynorphin 1 - 13
- Where
- United States
- Sponsor
- University of Minnesota
Opiate Withdrawal Syndrome
Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts
This is an open-label, randomized, 2-sequence, cross-over study evaluating the difference of efficacy between ear acupressure alone and ear acupressure plus electroacupuncture therapy both combined with methadone treatment…
- Trial name
- AAMTH (NCT03012373)
- Testing
- Ear acupressure alone, Electroacupuncture plus ear acupressure
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Lu-Tung Christian Hospital
Alcohol Withdrawal Syndrome, Alcohol Dependence
Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results.
- Trial name
- GATE I (NCT02090504)
- Testing
- Sodium Oxybate (SMO), Oxazepam
- Where
- 3 sites in Austria, Italy
- Volunteers
- 127 people
- Sponsor
- Catholic University of the Sacred Heart
Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine.
- Trial name
- B-PHORE (NCT03608696)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Substance Withdrawal Syndrome
Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
The purpose of this study is to see whether adults who use e-cigarettes every day experience symptoms of nicotine withdrawal when they stop using e-cigarettes for 6 days.
- Trial name
- NCT02825459
- Testing
- Abstinence from e-cigarettes
- Where
- 2 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Opioid Dependence
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
- Trial name
- PRO-810 (NCT00768482)
- Testing
- Probuphine (buprenorphine implant), Sublingual Buprenorphine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Titan Pharmaceuticals
Cocaine-Related Disorders, Substance Withdrawal Syndrome
Acute Withdrawal From Smoked Cocaine - 9
The purpose of this study is to develop an experimental paradigm to examine acute withdrawal symptoms from cocaine.
- Conditions
- Cocaine-Related Disorders, Substance Withdrawal Syndrome, Substance-Related Disorders
- Trial name
- NCT00000292
- Testing
- Cocaine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)